DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,330 | +0.4% | 840 | +43.6% | 0.00% | – |
| Q2 2023 | $17,263 | +14.2% | 585 | -10.8% | 0.00% | – |
| Q1 2023 | $15,114 | +18.9% | 656 | +43.5% | 0.00% | – |
| Q4 2022 | $12,709 | -15.3% | 457 | -9.1% | 0.00% | – |
| Q3 2022 | $15,000 | +15.4% | 503 | +10.1% | 0.00% | – |
| Q2 2022 | $13,000 | -27.8% | 457 | -18.2% | 0.00% | – |
| Q1 2022 | $18,000 | -10.0% | 559 | +25.9% | 0.00% | – |
| Q4 2021 | $20,000 | -9.1% | 444 | +1.4% | 0.00% | – |
| Q3 2021 | $22,000 | -40.5% | 438 | -8.4% | 0.00% | – |
| Q2 2021 | $37,000 | +37.0% | 478 | +2.6% | 0.00% | – |
| Q1 2021 | $27,000 | -18.2% | 466 | +18.0% | 0.00% | – |
| Q4 2020 | $33,000 | +560.0% | 395 | +180.1% | 0.00% | – |
| Q3 2020 | $5,000 | +150.0% | 141 | +67.9% | 0.00% | – |
| Q2 2020 | $2,000 | – | 84 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |